Innovating clearly

Make real-world data an essential leverage for the success of your projects.

The company
Our solutions

A personalised, innovative solution for optimising the use of real-world data.

We will accompany you during the creation of innovative healthcare studies, the analysing of real-world care of patients, and the practices of healthcare professionals, particularly in rare diseases. Our approach offers a new perspective for improving access to, developing, and re-evaluation of your therapeutic and organisational solutions.

Design of protocols for innovative studies

Collecting and analysing of real-world data

Medical writing and valorisation of results

Assisting with the implementation of projects to improve the healthcare pathway, including the research and the financing.

Our Expertise

Real-world data are essential for:

Identify unmet medical needs regarding medical practice and guidelines

Collaborating with patient representatives

Enhance screening

Reduce diagnostic and therapeutic errors

Complement and validate results from randomised controlled studies in a heterogeneous population (various comorbidities)

Harmonise diagnostic, therapeutic, and follow-up practices

Evaluate the effectiveness and correct use of treatments

Optimise healthcare coordination

Improve the quality of life of patients

Optimise the relationship between patients and healthcare professionals

Negotiate with Healthcare Authorities

Increase knowledge and develop research

Carely in brief.

0rare diseases studied
0years of experience in heavily medicalised therapeutic domains
0Healthcare Professional solicited
0Communications at congresses
0Publications
0Innovative projects accompanying clients
0Early access projects
0Studies that provided evidence of increased “added medical value” (ASMR)

Our accompanying.

The solutions for collecting and analysing real-world data to accompany each phase of the life cycle of your innovation
The life cycles of your innovation are driven by the timelines imposed by the Health Authorities: early access, marketing authorisation, reimbursement, and reinscription.
At every step, numerous challenges emerge that can be overcome using real-world data.

Step 1 Access

Step 2 Development

Step 3 Reevaluation

Access

Demonstrate the medical value of your innovation.

The existence of an unmet medical need

Status of the healthcare pathway

Definition and size of the targeted population

Evidence for the reimbursement dossier (first inscription)

Development

Create an effective ecosystem surrounding your innovation

Status of medical practice

Status of knowledge

Evaluation of the impact of the disease and the quality of life

Impact of your medication on healthcare management

Implementing of solutions to improve the healthcare pathway (editing of clinical practice recommendations, projects to accompany patients by pharmacists, tele-expertise, creation and validation of instruments (particularly quality of life and identifying patient profiles), developing of registries using AI, and patient applications)

Validation of clinical trials

Reevaluation

Gaining insight into the experience associated with your innovation in everyday practice

Prescriptions and use

Effectiveness, tolerance, observance, quality of life

Impact on morbidity and mortality

Impact on the healthcare system (evaluation of direct and indirect costs)

Our solutions.

Surveys

Medical practice surveys regarding healthcare pathways

Research

Accompanying and clinical research in pharmacies

Writing

Medical writing and animating advisory boards

Access

Market access surveys (unmet needs, target population)

Artificial Intelligence

Real-world studies using registries generated by AI and complemented with data from patient applications

Our solutions

Projects performed using a network of partners and experts

Thanks to close collaboration with independent experts, Carely can offer an enriched approach and solutions adapted to the specific needs of our clients.

Our partners

Our experts

Discover

Actuality

April 2025

New website launch

New website launch

Site launched on 15/04/25

A successful project conducted in just a few months, thanks to the team’s vision for the future and the talent of the communication agency Atelier Siioux.

https://atelier-siioux.com/

Publications

2022
Lung disease

Mornex J-F, Balduyck M, 
Bouchecareih M, et al.

French clinical practice guidelines for the diagnosis and management of lung disease with alpha 1-antitrypsin deficiency.

 

Manuscripts
2024
Hereditary angioedema

Boccon-Gibod I, Gobert D, Gauthier M, et al.
Evaluation of Adherence to Berotralstat in Patients with Hereditary Angioedema: A Prospective Survey in Community Pharmacies. Journal of Allergy and Clinical Immunology. 2024;153(2):AB8.

Manuscripts
2024
Amyloidosis

Oghina S, Legallois D, 
Fournier P, et al.
Evaluating the current physicians’ knowledge and patients’ pathways for diagnosing transthyretin cardiac amyloidosis (ATTR-CM) in France: An extensive survey of diverse medical specialists. Archives of Cardiovascular Diseases.

Manuscripts
2023
Hereditary angioedema

Launay D, Bouillet L, Boccon-gibod I, et al.

Mise au point sur les angiœdèmes héréditaires et leurs nouvelles thérapeutiques. La Revue de Médecine Interne. 2023;44.

Manuscripts
All publications

They trusted us

Carely, a unique expertise to transform data into concrete actions and improve the diagnosis of rare diseases.

Thanks to Carely, we were able to obtain a clear and detailed vision of the diagnostic pathway for transthyretin and AL cardiac amyloidosis from different [medical] specialists. This allowed us to identify areas to improve the early diagnosis and allow for improved prognosis of patients.
Pr Thibaud Damy
Heart Failure and Amyloidosis unit, APHP-Henri Mondor Hospital
Show the medical value of an innovation in the context of a marketing authorization.

Carely generated, within the time allocated, critical real-world data for the “commission de transparence”, notably concerning the unmet medical need and the targeted population.
Nathalie Telmon
Market Access Manager France & Benelux, Blueprint Medicines (France) SAS
Carely, a key partner in the rare disease ecosystem that contributes to decreasing diagnostic errors.

An excellent capacity to analyze and decrypt the healthcare pathway in a dynamic manner that catalyzed a real evolution in the healthcare management of patients and allowed us internally to decide.
Valérie Rizzi-Puechal
Rare Diseases Lead France Pfizer Innovative Health
Carely, “human”, in terms of the size, the approach, and the nature of the relationships.

At an important moment, when novel therapies became available within the therapeutic strategy for auto-immune myasthenia, the analysis of the current management provided evidence of the unmet needs and also allowed us to identify strategies to improve and to develop new projects with all the role players in the [rare disease] network ecosystem.
François Denis
Director Medical Affairs & Evidence Generation, France

Contact